Mylod%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520at

## Overview Mylotat is a brand name for **Atropine Sulfate**, an anticholinergic medication. ## Primary Indications * Bradycardia (slow heart rate) * Organophosphate poisoning (antidote) * Preoperative medication to reduce secretions and prevent bradycardia ## Adult Dosing * **Bradycardia:** Typically 0.5 mg to 1 mg intravenously every 3 to 5 minutes as needed. The maximum dose is usually 0.04 mg/kg, not to exceed 3 mg total. In specific settings like ACLS protocols, doses may vary. * **Organophosphate Poisoning:** Dosing is highly variable and depends on the severity of poisoning. It can range from 1 mg to 4 mg intravenously every 5-60 minutes until symptoms improve or signs of atropinization (tachycardia, dry mouth, mydriasis) appear. Doses may need to be significantly higher and more frequent than for bradycardia. * **Preoperative:** 0.4 mg to 0.6 mg intramuscularly or intravenously 30 to 60 minutes before surgery. ## Pediatric Dosing * **Bradycardia:** 0.02 mg/kg intravenously, with a minimum dose of 0.1 mg and a maximum dose of 0.5 mg per dose. Doses can be repeated every 5 minutes up to a total of 1 mg (or 0.04 mg/kg, whichever is less). * **Organophosphate Poisoning:** Dosing is highly variable and depends on the severity of poisoning. Consult specialized pediatric toxicology resources. ## Dose Adjustments * **Renal Impairment:** No specific dose adjustment is typically recommended, but caution may be warranted in severe renal impairment. * **Hepatic Impairment:** No specific dose adjustment is typically recommended. ## Contraindications * Known hypersensitivity to atropine. * Tachycardia. * Certain types of glaucoma (narrow-angle glaucoma). * Certain cardiac conditions (e.g., unstable cardiovascular status in shock). ## Adverse Effects Common adverse effects are related to its anticholinergic properties: dry mouth, blurred vision, photophobia, dilated pupils (mydriasis), constipation, urinary retention, increased heart rate (tachycardia), decreased sweating, fever, confusion, dizziness, and hallucinations. ## Key Drug Interactions * **Other Anticholinergics:** Additive anticholinergic effects. * **Beta-blockers:** May exacerbate atropine-induced tachycardia. * **Prokinetic agents (e.g., metoclopramide):** May antagonize the effects of prokinetic agents. * **Potassium Chloride:** Oral potassium chloride given with slow-release formulations can cause gastrointestinal lesions. ## Monitoring * Heart rate and rhythm. * Blood pressure. * Signs and symptoms of anticholinergic toxicity (dry mouth, blurred vision, confusion, urinary retention). * For organophosphate poisoning: level of consciousness, respiratory status, secretions, and signs of atropinization. ## Clinical Pearls * Atropine is dosed in milligrams (mg), not micrograms, for bradycardia and preoperative use. However, for pediatric bradycardia, the dose is typically in micrograms per kilogram (mcg/kg). * For organophosphate poisoning, much higher doses of atropine may be required than for bradycardia. * The intravenous route is preferred for rapid onset in emergencies. * Intramuscular administration is suitable for preoperative use. *** *This information is for educational purposes and does not substitute for current prescribing information or clinical judgment. Always verify with the most recent drug information from reputable sources and consider individual patient factors.*